NCT01927055View on ClinicalTrials.gov

A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy

PHASE3TerminatedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Symptomatic Neurogenic Orthostatic HypotensionParkinson's DiseaseMultiple Systems AtrophyPure Autonomic FailureDopamine Beta Hydroxylase Deficiency
Interventions
DRUG

Droxidopa

Droxidopa at 100 mg, 200 mg, 300 mg

DRUG

Placebo

Placebo to match droxidopa capsules and strength designations

Trial Locations (3)

10016

NYU Langone Medical Center, New York

28277

Information on additional locations involved in this clinical trial contact Chelsea Therapeutics, Charlotte

53233

Wisconsin Institute for Neurology and Sleep Disorders, Milwaukee

Sponsors
All Listed Sponsors
lead

Chelsea Therapeutics

INDUSTRY